Reports
Reports
Sale
Based on the geographic analysis of the market, North America, particularly, the United States dominates the regional market with the market size valued at USD 13.061 billion in 2023. The rising prevalence of infectious diseases and growing preference for personalized medicine are some of the key factors likely to drive the market growth during the forecast period.
Further, the increasing research and development activities are also boosting the market share in the region. For instance, in July 2023 , a group of researchers at Queensland University of Technology (QUT) developed a new approach for designing molecular ON-OFF switches based on proteins with widespread application in biotechnological, biomedical, and bioengineering. The research team mentioned that this novel approach will enable them to develop diagnostic tests for the early detection of diseases that are designed and built faster and with more accuracy. Such developments are anticipated to propel advancements in molecular diagnostic methods, thereby elevating the market value.
Molecular Diagnostics Market Size
Molecular Diagnostics Market Growth
Molecular Diagnostics Market Trends
Molecular Diagnostics Market Share
Molecular Diagnostics Regional Analysis
Molecular Diagnostics Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Molecular Diagnostics Market Overview
3.1 Global Molecular Diagnostics Market Historical Value (2017-2023)
3.2 Global Molecular Diagnostics Market Forecast Value (2024-2032)
4 Global Molecular Diagnostics Market Landscape
4.1 Global Molecular Diagnostics: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Type
4.1.3 Analysis by Indication
4.2 Global Molecular Diagnostics: Product Landscape
4.2.1 Analysis by Product & Service
4.2.2 Analysis by Technology
4.2.3 Analysis by Application
5 Global Molecular Diagnostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Molecular Diagnostics Market Segmentation (2017-2032)
6.1 Global Molecular Diagnostics Market (2017-2032) by Product & Service
6.1.1 Market Overview
6.1.2 Instruments
6.1.3 Reagents & Kits
6.1.4 Services & Software
6.2 Global Molecular Diagnostics Market (2017-2032) by Test Location
6.2.1 Market Overview
6.2.2 Point-of-Care
6.2.3 Self-test or Over the Counter
6.2.4 Central Laboratories
6.3 Global Molecular Diagnostics Market (2017-2032) by Technology
6.3.1 Market Overview
6.3.2 Polymerase Chain Reaction (PCR)
6.3.3 In Situ Hybridization
6.3.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.3.5 Chips and Microarrays
6.3.6 Mass Spectrometry
6.3.7 Sequencing
6.3.8 Transcription Mediated Amplification
6.3.9 Others
6.4 Global Molecular Diagnostics Market (2017-2032) by Application
6.4.1 Market Overview
6.4.2 Oncology
6.4.2.1 Breast Cancer
6.4.2.2 Colorectal Cancer
6.4.2.3 Lung Cancer
6.4.2.4 Prostate Cancer
6.4.2.5 Other Cancers
6.4.3 Pharmacogenomics
6.4.4 Infectious Diseases
6.4.4.1 Hepatitis
6.4.4.2 HIV
6.4.4.3 CT/NG
6.4.4.4 Hospital Acquired Infections (HAI)
6.4.4.5 HPV
6.4.4.6 Tuberculosis
6.4.4.7 Influenza
6.4.4.8 Other Infectious Diseases
6.4.5 Genetic Testing
6.4.6 Neurological Diseases
6.4.7 Cardiovascular Diseases
6.4.8 Microbiology
6.4.9 Others
6.5 Global Molecular Diagnostics Market (2017-2032) by End User
6.5.1 Market Overview
6.5.2 Diagnostic Laboratories
6.5.3 Hospitals & Clinics
6.5.4 Other End Users
6.6 Global Molecular Diagnostics Market (2017-2032) by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Molecular Diagnostics Market (2017-2032)
7.1 North America Molecular Diagnostics Market (2017-2032) by Product and Service
7.1.1 Market Overview
7.1.1 Instruments
7.1.2 Reagents & Kits
7.1.3 Services & Software
7.2 North America Molecular Diagnostics Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Polymerase Chain Reaction (PCR)
7.2.3 In Situ Hybridization
7.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.2.5 Chips and Microarrays
7.2.6 Mass Spectrometry
7.2.7 Sequencing
7.2.8 Transcription Mediated Amplification
7.2.9 Others
7.3 North America Molecular Diagnostics Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Molecular Diagnostics Market (2017-2032)
8.1 Europe Molecular Diagnostics Market (2017-2032) by Product and Service
8.1.1 Market Overview
8.1.2 Instruments
8.1.3 Reagents & Kits
8.1.4 Services & Software
8.2 Europe Molecular Diagnostics Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Polymerase Chain Reaction (PCR)
8.2.3 In Situ Hybridization
8.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
8.2.5 Chips and Microarrays
8.2.6 Mass Spectrometry
8.2.7 Sequencing
8.2.8 Transcription Mediated Amplification
8.2.9 Others
8.3 Europe Molecular Diagnostics Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Molecular Diagnostics Market (2017-2032)
9.1 Asia Pacific Molecular Diagnostics Market (2017-2032) by Product and Service
9.1.1 Market Overview
9.1.2 Instruments
9.1.3 Reagents & Kits
9.1.4 Services & Software
9.2 Asia Pacific Molecular Diagnostics Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Polymerase Chain Reaction (PCR)
9.2.3 In Situ Hybridization
9.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
9.2.5 Chips and Microarrays
9.2.6 Mass Spectrometry
9.2.7 Sequencing
9.2.8 Transcription Mediated Amplification
9.2.9 Others
9.3 Asia Pacific Molecular Diagnostics Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Molecular Diagnostics Market (2017-2032)
10.1 Latin America Molecular Diagnostics Market (2017-2032) by Product and Service
10.1.1 Market Overview
10.1.2 Instruments
10.1.3 Reagents & Kits
10.1.4 Services & Software
10.2 Latin America Molecular Diagnostics Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Polymerase Chain Reaction (PCR)
10.2.3 In Situ Hybridization
10.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
10.2.5 Chips and Microarrays
10.2.6 Mass Spectrometry
10.2.7 Sequencing
10.2.8 Transcription Mediated Amplification
10.2.9 Others
10.3 Latin America Molecular Diagnostics Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Molecular Diagnostics Market (2017-2032)
11.1 Middle East and Africa Molecular Diagnostics Market (2017-2032) by Product and Service
11.1.1 Market Overview
11.1.2 Instruments
11.1.3 Reagents & Kits
11.1.4 Services & Software
11.2 Middle East and Africa Molecular Diagnostics Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Polymerase Chain Reaction (PCR)
11.2.3 In Situ Hybridization
11.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
11.2.5 Chips and Microarrays
11.2.6 Mass Spectrometry
11.2.7 Sequencing
11.2.8 Transcription Mediated Amplification
11.2.9 Others
11.3 Middle East and Africa Molecular Diagnostics Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Market Share by Top 5 Companies
18.2 BioMérieux SA
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisition
18.2.5 Certifications
18.3 BD
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisition
18.3.5 Certifications
18.4 Bio-Rad Laboratories, Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisition
18.4.5 Certifications
18.5 Abbott
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisition
18.5.5 Certifications
18.6 Agilent Technologies, Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisition
18.6.5 Certifications
18.7 Hologic Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisition
18.7.5 Certifications
18.8 Danaher Corporation
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisition
18.8.5 Certifications
18.9 DiaSorin
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisition
18.9.5 Certifications
18.10 Illumina, Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisition
18.10.5 Certifications
18.11 Johnson & Johnson Services, Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisition
18.11.5 Certifications
18.12 QIAGEN N.V.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisition
18.12.5 Certifications
18.13 F. Hoffmann-La Roche, Ltd.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisition
18.13.5 Certifications
18.14 PerkinElmer, Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisition
18.14.5 Certifications
18.15 Siemens Healthineers
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisition
18.15.5 Certifications
18.16 Thermo Fisher Scientific Inc.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Mergers and Acquisition
18.16.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.